Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Dana Rifai"'
Autor:
Taha Alrifai, Faisal Shaukat Ali, Sameer Saleem, Diana Carolina Miranda Ruiz, Dana Rifai, Sundas Younas, Faisal Qureshi
Publikováno v:
Case Reports in Oncological Medicine, Vol 2019 (2019)
Immune checkpoint inhibitors (ICPIs) are a breakthrough therapy in oncology and have been approved by the Food and Drug Administration for the treatment of several malignancies. ICPIs have been reported to cause immune-mediated damage of islet cells
Externí odkaz:
https://doaj.org/article/25efb9ee43ca425d855c5f2e846e385b
Autor:
Diana Miranda Ruiz, Taha Alrifai, Faisal Ali, Sameer Saleem, Faisal Qureshi, Sundas Younas, Dana Rifai
Publikováno v:
Case Reports in Oncological Medicine
Case Reports in Oncological Medicine, Vol 2019 (2019)
Case Reports in Oncological Medicine, Vol 2019 (2019)
Immune checkpoint inhibitors (ICPIs) are a breakthrough therapy in oncology and have been approved by the Food and Drug Administration for the treatment of several malignancies. ICPIs have been reported to cause immune-mediated damage of islet cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfa393b0fdd5a6ffb571e2307f96c276
http://europepmc.org/articles/PMC6875347
http://europepmc.org/articles/PMC6875347
Publikováno v:
Molecular and Clinical Oncology.
Bevacizumab (BV) is a humanized monoclonal antibody that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF). The addition of BV to combination chemotherapy has been shown to improve the outcomes in several malignancies, incl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::956391869ae9aae08dd5f8b972dfe26b
https://doi.org/10.3892/mco.2019.1868
https://doi.org/10.3892/mco.2019.1868
Publikováno v:
Chest. 145:173-177
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0088d28b71609af0ae95e9424d13cc43
https://doi.org/10.1378/chest.13-1312
https://doi.org/10.1378/chest.13-1312
Publikováno v:
American journal of therapeutics. 23(6)
The drug rash with eosinophilia and systemic symptoms syndrome also known as DRESS syndrome refers to an idiosyncratic drug reaction commonly characterized by rashes, fever, lymphadenopathy, and internal organ involvement. We report a case of this sy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96a93b3c3cbc0e2f3ca27ed6b3c21894
https://pubmed.ncbi.nlm.nih.gov/27574928
https://pubmed.ncbi.nlm.nih.gov/27574928
Publikováno v:
Chest. 145:1176-1177
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61b4ca99bc0d32492257892510cd46f9
https://doi.org/10.1378/chest.14-0340
https://doi.org/10.1378/chest.14-0340
Publikováno v:
Chest. 138:506A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c23fd4d1da2d9c0ec840318f94dc4fc
https://doi.org/10.1378/chest.9967
https://doi.org/10.1378/chest.9967